Core Insights - Vitamin B12, also known as cobalamin, is essential for human health, playing a critical role in nerve function and preventing pernicious anemia. It is used in the treatment of various diseases such as cerebral hemorrhage, Alzheimer's disease, and acute myelitis. The market demand for Vitamin B12 supplements is increasing due to rising health awareness among consumers. The market size of the cobalamin industry in China is projected to reach 1.4 billion yuan in 2024, representing a year-on-year growth of 6% [1][10]. Industry Overview - Cobalamin, or Vitamin B12, is the only vitamin that contains a metal element. It is a red crystalline powder that is water-soluble and plays multiple indispensable roles in the human body, including maintaining a healthy nervous system and promoting red blood cell production [3][10]. - The primary sources of Vitamin B12 are animal products, with some plant sources like soybeans containing lower amounts. The vitamin is crucial for protein and amino acid synthesis, especially in infants [3]. Market Dynamics - China is a major supplier of Vitamin B12 globally, with significant export volumes. The export quantity of unblended Vitamin B12 and its derivatives is expected to grow from 355.08 tons in 2020 to 498.08 tons by 2024 [10]. - The competition in the cobalamin market is intensifying due to limited market size and high domestic production capacity. Major players include Hebei Huaron, Yuxing Bio, Ningxia Jinyi, and Jiutian Pharmaceutical [10][11]. Production Methods - The cobalamin industry primarily utilizes microbial fermentation methods for production, as chemical synthesis is complex and costly. The fermentation process mainly involves anaerobic fermentation using Propionibacterium and aerobic fermentation using Pseudomonas [8]. Industry Trends - The cobalamin industry is expected to see continuous technological innovation, focusing on refining extraction methods and enhancing product stability. The use of biotechnological advancements will likely lead to higher activity and lower impurity levels in cobalamin products [12]. - There is a trend towards high-end and diversified product offerings to meet varying consumer needs, including specialized products for anemia treatment and a wider range of dosage forms [13]. - The industry is moving towards environmentally sustainable practices, including green sourcing of raw materials and energy-efficient extraction processes [14].

Group 1 - The core viewpoint of the article highlights that Wanbangde's self-developed innovative small molecule cyclic peptide drug (MCR cyclic peptide) shows superior weight loss effects compared to the existing star drug GLP-1 peptide in preclinical studies on DB/DB obese mouse models [1] - The drug also demonstrates muscle preservation and comprehensive regulation of metabolic indicators such as blood sugar and blood lipids, indicating potential for differentiated clinical options [1] - Wanbangde has established a comprehensive R&D system and a highly skilled team, transitioning from generic drugs to innovative drugs, focusing on the development of traditional Chinese medicine, chemical drugs, and raw materials [1] Group 2 - As of the first half of this year, Wanbangde holds 67 patents in the pharmaceutical manufacturing sector, including 50 invention patents, 14 utility model patents, and 3 design patents [1] - The company’s key product, Huperzine A, has obtained patents in the United States, Europe, and Japan, with an additional 7 patents expected to be added by the first half of 2025 [1] - The company plans to continue advancing the preclinical pharmacology and toxicology studies of its peptide new drugs, aiming to bring differentiated medications to patients with relevant treatment needs [2]

2025 年 02 月 17 日 行业周报 看好/维持 医药 医药 Galderma 单抗 Nemluvio 获欧盟批准 ◼ 走势比较 报告摘要 市场表现： 2025 年 2 月 17 日，医药板块涨跌幅+0.66%，跑赢沪深 300 指数 0.45pct，涨跌幅居申万 31 个子行业第 12 名。各医药子行业中，医院 (+3.51%)、医疗研发外包(+3.24%)、体外诊断（+2.95%）表现居前，线下 药店（-1.92%)、其他生物制品(-0.15%)、血液制品（+0.18%)表现居后。 个股方面，日涨幅榜前 3 位分别为泓博医药(+20.01%)、安必平(+20.00%)、 天智航(+16.65%)；跌幅榜前 3 位为羚锐制药（-4.49%）、马应龙(-4.40%)、 昆药集团（-3.59%)。 公司要闻： 万邦德（002082）：公司发布公告，子公司万邦德制药集团有限公司 于 2025 年 2 月 13 日收到美国 FDA 的认定函，甲钴胺用于治疗肌萎缩侧 索硬化（ALS，即渐冻症）获得 FDA 授予的孤儿药资格认定。甲钴胺是甲 硫氨酸合成酶的辅酶，催化同型半胱氨酸转化为甲硫氨酸，从而维持甲基 化循环 ...